Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Sarcoma 4Glioma 4Thyroid Neoplasms 3Colorectal Neoplasms 3Central Nervous System Neoplasms 3Wilms Tumor 2Solid Tumors Harboring NTRK Fusion 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Neoplasms 2Multiple Myeloma 2Melanoma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Lung Neoplasms 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Ependymoma 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Xanthogranuloma, Juvenile 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Tumors Harboring NTRK Fusion 1Stomach Neoplasms 1

Interventions

trametinib 1selpercatinib 1pralsetinib 1lenvatinib 1larotrectinib 1entrectinib 1dabrafenib 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Thyroid Cancer Patients Who Received Target Therapy × larotrectinib × Clear all
NCT06195228 2025-08-14

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Fudan University

Phase 4 Recruiting
800 enrolled
EndocrineHead & Neck

Advanced Thyroid Cancer Patients Who Received Target Therapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡